

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



Hua Han Health Industry Holdings Limited

華瀚健康產業控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 587)

## RESUMPTION CONDITIONS

This announcement is made by Hua Han Health Industry Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“**SFO**”) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to (i) the announcement of the Company dated 30 September 2016 in relation to the audit progress of the 2015/2016 Audit Work and the adjournment of the Board meeting and delay in publication of annual results of the Group for the year ended 30 June 2016; (ii) the announcement of the Company dated 19 October 2016 in relation to the establishment of independent board committee; and (iii) the announcement of the Company dated 21 November 2016 in relation to the appointment of an independent third party investigator (collectively, the “**Announcements**”). Unless otherwise defined, the capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

On 9 December 2016, the Board received a letter (“**Letter**”) from the Stock Exchange, in which the Stock Exchange stated the following conditions (“**Resumption Conditions**”) for the resumption of trading in the shares of the Company:

- (a) complete an appropriate investigation on matters identified by EY, disclose the findings of the investigation, assess the impact on the Company’s financial and operational positions, and take appropriate remedial actions;
- (b) publish all outstanding financial results required under the Listing Rules and address any audit qualifications; and
- (c) inform the market of all material information for shareholders and investors to appraise the Group’s position.

The Stock Exchange noted that it may modify the above and/or impose further conditions if the situation changes.

The Company is now taking appropriate steps to fulfill the Resumption Conditions and will keep its shareholders and potential investors informed of the progress as and when appropriate.

## **SUSPENSION OF TRADING**

At the request of the Company, trading in the Company's shares (stock code: 00587) and debt securities (stock code: 05676) have been suspended on The Stock Exchange of Hong Kong Limited with effect from 9:00 a.m. on Tuesday, 27 September 2016 and will remain suspended until further notice.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board of  
**Hua Han Health Industry Holdings Limited**  
**Zhang Peter Y.**  
*Chairman*

Hong Kong, 12 December 2016

*As at the date of this announcement, the Board comprises Mr. Zhang Peter Y., Mr. Deng Jie, Mr. Zhou Chong Ke, Mr. Chen Lei and Mr. Luo Zhan Biao as executive Directors, Mr. Tarn Sien Hao as non-executive Director, and Professor Lin Shu Guang, Professor Zhou Xin and Mr. Tso Sze Wai as independent non-executive Directors.*